The pathophysiological response to infection with P falciparum is highly variable. It depends on several different factors including previously acquired immunity and the production of cytokines such as interleukin-1 (IL-1) and tumour necrosis factor (TNF), y-interferon (y-IFN), and interleukin-6 (IL-6). Secretion of these mediators is thought to be responsible for many Immulon 2 (Dynatech) microtitre plates were coated with affinity purified antibodies to human C-reactive protein and serum amyloid A (derived in rabbit and goat, respectively) by incubation overnight at 4°C in bicarbonate buffer (pH 9 2) . Serum specimens were diluted in phosphate buffered saline with 0-05% Tween-20 (pH 7-5) (PBS-Tween). Diluted sample (100 ll) was added to a microtitre well together with 100 pl of alkaline-phosphatase conjugated C-reactive protein or serum amyloid A and incubated for one hour at room temperature in a humidified chamber. The optimal concentration for all of the reagents was previously determined by chequerboard titration. After washing the plates p-nitrophenyl phosphate substrate was added, and the resulting colour change measured using a Dynatech 600 ELISA reader at 405 nm. The concentration of Creactive protein or serum amyloid A present in the sample was determined by calculation from a series of standard concentrations of highly purified C-reactive protein or high density lipoprotein (HDL) tested in parallel on the same plate.
Results
Fifteen of the 17 patients had raised concentrations of C-reactive protein (> 10 mg/l) and conscious level, hypotension, or detecting other signs indicating the development of complications. Laboratory markers have also been studied, and severity of malaria has been associated with higher parasitaemia, a fall in serum sodium and albumin concentration, low platelet counts and a rise in serum bilirubin and urea concentrations. Measurements of parasitaemia have drawbacks as markers of severity as semi-immune people may tolerate levels of parasitaemia which would be associated with severe disease in non-immune subjects. The study reported here used nonimmune subjects with mild to moderate infection, in whom malaria was the only diagnosis, to reduce non-specific confouding effects. Recent research has confirmed the importance of leucocyte mediators such as TNF in the pathogenesis of severe malaria. Even in severe disease cytokine concentrations remain in the picogramme per ml range. This low concentration is coupled with a short plasma half-life, making measurement difficult in the clinical setting. A study of TNF concentrations in 75 Gambian children with acute P falciparum malaria failed to show a correlation between the concentration ofTNF and severity of disease, although increased TNF concentrations were found more often in patients with complications.2 In a study in Germany of patients with P falciparum and P vivax, however, serum IL-6, measured using a bioassay and TNF measured by ELI SA, was shown to be correlated with the presence of severe complications. Moreover, serum concentrations fell in response to antimalarial chemotherapy.4 In a study of 65 children with severe Pfalciparum malaria in Malawi the mean initial serum concentration of TNF was significantly higher in the 10 patients who died than in the 55 who survived.12 High concentrations of TNF were also associated with hypoglycaemia, hyperparasitaemia, and severity of illness as measured by a prognostic index.
A secondary consequence of cytokine production is the stimulation of the acute phase reaction. Studies of sequential acute phase reactants concentrations have been correlated with severity of bacterial infection and therapeutic reponse to specific antibacterial treatment.
This pilot study shows significant correlations between conventional laboratory markers of severity of malaria-parasite count, serum sodium and albumin-with acute phase reac- It has been suggested that laboratory variables which show improvement in response to treatment, such as urea, glucose, platelet count, etc, would be valuable in the assessment of response to antimalarial chemotherapy but this possibility has not been shown in prospective studies.
Each of the patients in this study showed a consistent fall in acute phase reactant concentrations over the period of antimalarial treatment. Although individual values could vary, sometimes increasing, there was a consistent downward trend. The concentrations of acute phase reactants were found to be increased on the second day of the hospital admission in all patients studied; this is consistent with an increase in parasitaemia which occurs commonly up to 18 hours after starting antimalarial chemotherapy.
These data support the idea that sequential measurement of acute phase reactant concentrations are valuable in the assessment of the clinical course of patients with acute P falciparum malaria. Clinicians monitoring treatment in this way must be alert to the variation which occurs and observe the overall trend.
